{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.8","upperLimit":"79.2","value":"69.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"CR rate is defined as the percentage of participants with a CR according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2014).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg).","id":"OG000","title":"Treatment-naive Open-label Arm"}],"paramType":"NUMBER","populationDescription":"All Enrolled Treatment-Naïve Participants","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 40.51 months","title":"Complete Response (CR) Rate (Treatment-Naive Arm)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}